A5002656845- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Surgical Simulation and Training
- Urologic and reproductive health conditions
- Ovarian cancer diagnosis and treatment
- Minimally Invasive Surgical Techniques
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Immune cells in cancer
- Anorectal Disease Treatments and Outcomes
- Cancer, Stress, Anesthesia, and Immune Response
- Congenital Anomalies and Fetal Surgery
- Multiple and Secondary Primary Cancers
- Pelvic floor disorders treatments
- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Surgical Sutures and Adhesives
Morinomiya Hospital
2024
National Cancer Center Hospital East
2018-2024
Institute of Cancer Research
2023
Fujieda Municipal General Hospital
2023
Hamamatsu University School of Medicine
2014-2022
National Cancer Center
2021
Chiba Cancer Center
2021
Preoperative chemoradiotherapy (CRT) and surgical resection are the standard treatment for locally advanced rectal cancer (LARC). Combining immune checkpoint inhibitors with radiation suggests a promising approach enhancing efficacy. We investigated efficacy of CRT followed by nivolumab surgery in patients LARC.In phase I, we feasibility sequentially combined CRT, 5 cycles nivolumab, radical surgery. In II, microsatellite stable (MSS) instability-high (MSI-H) LARC were evaluated.Three I...
4100 Background: Chemoradiotherapy (CRT) followed by radical surgery (S) is standard therapy for patients (pts) with locally advanced rectal cancer (LARC). Sequential use of an anti-PD-1 antibody after radiation demonstrates synergistic effects in vivo models, and effective pts microsatellite instability-high (MSI-H) metastatic colorectal (mCRC). We studied nivolumab (nivo) S following CRT (50.4 Gy capecitabine 1,650 mg/m 2 ) T 3–4 N any M 0 LARC. Methods: After the quality-assured CRT, 240...
108 Background: In VOLTAGE-A, CRT (50.4 Gy with capecitabine of 1,650 mg/m 2 ) followed by five cycles consolidation Nivo (240 mg q2 weeks [W]) and radical surgery showed 30% pathological complete response (pCR) in pts MSS 60% MSI-H T 3–4 N any M 0 LARC. Here, we report survival outcomes functional results. Methods: All 39 5 were included the VOLTAGE-A from Jan 2017 to Oct 2019. Survival outcomes, late adverse events, patient-reported outcome measurements for urogenital anal functions...
Patients with colorectal cancers (CRCs) generally exhibit improved survival through intensive lymph node (LN) dissection. However, recent progress in cancer immunotherapy revisits the potential importance of regional LNs, where T cells are primed to attack tumor cells. To elucidate role LN, we investigated immunological status nonmetastatic LN lymphocytes (LNLs) comparison those microenvironment (tumor-infiltrating lymphocytes; TILs) using flow cytometry and next-generation sequencing. LNLs...
3606 Background: Chemoradiotherapy (CRT) with surgery (S) is standard for patients (pts) locally-advanced rectal cancer (LARC), and nivolumab (nivo) active in microsatellite instability-high (MSI-H) metastatic colorectal (mCRC). We studied nivo radical S following CRT (50.4 Gy capecitabine 1,650 mg/m 2 ) T 3–4 N any M 0 LARC. Methods: Phase I included testing of a recommended phase II dosing schedule (RP2S). Efficacy safety were pts those given RP2S I. In Cohort A-1, stable (MSS) LARC pts,...
Few reports detail adequate surgical management of giant pelvic tumors that traverse the sciatic foramen.We present a case retroperitoneal lipoma presented with dumbbell shape on imaging, occupying entire lesser pelvis and protruding to gluteus through foramen. Surgery was performed for en bloc resection tumor.A parasacral approach patient in prone position necessary dissect tumor buttock, manipulate around foramen preserve collateral blood flow gluteal muscle. An abdominal also essential...
100 Background: In VOLTAGE-A, chemoradiotherapy (CRT; 50.4Gy with capecitabine, 1,650mg/m 2 ) followed by five cycles of consolidation nivolumab (nivo) (240mg q2 weeks) showed 30% pathological complete response [pCR; AJCC tumor regression grade (TRG) 0] and 38% major responses (AJCC TRG 0-1) in patients microsatellite stable (MSS) locally advanced primary rectal cancer (LARC). addition, 60% pCR was observed instability-high (MSI-H) LARC. this study, we aimed to determine the predictive...
Introduction: Fluoropyrimidine-based Chemoradiotherapy (CRT) and subsequent radical surgery is widely accepted as the standard treatment for patients with Locally Advanced Rectal Cancer (LARC). Higher pathological complete response (pCR) rates are associated good clinical outcomes. Recently, improved therapeutic effects have been reported in various types of cancer by combining an immune checkpoint inhibitor radiotherapy (RT). The purpose this study to investigate safety, efficacy...
4073 Background: In VOLTAGE-A1, after 5 cycles of nivolumab (240 mg q2 weeks) plus radical surgery following chemoradiotherapy (CRT; 50.4 Gy with capecitabine 1,650 mg/m 2 ), a major pathologic response is observed in 38% (AJCC tumor regression grade 0-1) 37 patients microsatellite-stable locally advanced primary rectal cancer. Here, biomarkers for predicting the efficacy this treatment were investigated. Methods: Serial biopsies and blood collections performed at 4 time points; before CRT,...
58 Background: We previously reported tumor-infiltrating lymphocyte (TIL) dynamics predictive of pCR in microsatellite-stable (MSS) LARC. In the current analysis, we investigate whether an immune cell-to-cell spatial network may predict MSS Methods: VOLTAGE study is a phase I/II to evaluate efficacy chemoradiotherapy (CRT) followed by nivolumab and subsequent surgery LARC pts. H&E images multiplex immunofluorescence (mIF) containing total 35 markers for T cells, TAM, Myeloid-derived...
TPS878 Background: Fluoropyrimidine-based chemoradiotherapy (CRT) and subsequent radical surgery (SRS) are widely accepted as standard treatment for patients (pts) with locally advanced rectal cancer (LARC). Pathological complete remission (pCR) rates associated improved clinical outcomes. An important target, high-frequency microsatellite instability (MSI-H), was identified which anti-PD-1 antibodies confirmed robust antitumor activity in metastatic colorectal (mCRC). Recently, therapeutic...
症例は80歳，女性．食欲低下，腹部膨満，嘔吐を主訴に近医を受診し，イレウスの診断で当院に紹介された．来院時38.7℃の発熱，腹部膨満，下腹部の圧痛と腹膜刺激症状を認めた．炎症反応は高値であり，腹部造影CT検査およびMRI検査で，骨盤腔内に卵巣奇形腫を疑う腫瘍を認めた．腫瘍の内部にはガス像があり，S状結腸との交通が示唆された．保存的加療を行いながら全身精査した後，手術を施行した．左卵巣腫瘍はS状結腸に穿通し，強固に癒着していたため，左卵巣とS状結腸を一塊にして切除した．病理組織学的に腫瘍は卵巣皮様嚢腫より悪性転化をきたした扁平上皮癌と診断された．術後15カ月の現在，再発はみられていない．悪性転化を伴う卵巣皮様嚢腫に関する文献的考察を加えて報告する．
100 Background: Chemoradiotherapy (CRT) followed by curative resection in patients (pts) with local recurrence after radical surgery for primary rectal cancer is the preferred strategy if radiotherapy (RT) was not previously performed. In VOLTAGE-A study, nivolumab plus following CRT showed a promising pathologic complete response (pCR) rate of 30% pts microsatellite-stable (MSS) advanced cancer. The treatment sequence prospectively investigated Locally Recurrent Rectal Cancer (LRRC)...
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Instability–High Locally Advanced Rectal Cancer
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Instability–High Locally Advanced Rectal Cancer
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Instability–High Locally Advanced Rectal Cancer
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Instability–High Locally Advanced Rectal Cancer
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Instability–High Locally Advanced Rectal Cancer